Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proktis-M is a rectal suppository formulation developed by Farma-Derma and distributed in Canada by BioSyent Pharma. It is primarily composed of sodium hyaluronate, a polysaccharide that facilitates tissue repair and wound healing by maintaining a moist environment and providing structural support to the anorectal mucosa. The product is indicated for the treatment of conditions such as hemorrhoids, anal fissures, proctitis, and for promoting healing following proctological surgery. In addition to sodium hyaluronate, the formulation typically includes botanical extracts such as Calendula, Centella asiatica, Aloe vera, and tea tree oil, which contribute to its soothing and anti-inflammatory properties. It is often regulated as a medical device due to its mechanical action in protecting the mucosal barrier.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Proktis-M.